JPH05238942A - Antiulcerous agent - Google Patents
Antiulcerous agentInfo
- Publication number
- JPH05238942A JPH05238942A JP4075927A JP7592792A JPH05238942A JP H05238942 A JPH05238942 A JP H05238942A JP 4075927 A JP4075927 A JP 4075927A JP 7592792 A JP7592792 A JP 7592792A JP H05238942 A JPH05238942 A JP H05238942A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- organic solvent
- agent
- aqueous solution
- thumb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000767 anti-ulcer Effects 0.000 title abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 31
- 239000003960 organic solvent Substances 0.000 claims abstract description 13
- 239000007864 aqueous solution Substances 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 244000141009 Hypericum perforatum Species 0.000 claims description 6
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 6
- 239000003699 antiulcer agent Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract description 5
- 230000003902 lesion Effects 0.000 abstract description 4
- 208000007882 Gastritis Diseases 0.000 abstract description 2
- 230000023597 hemostasis Effects 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 abstract description 2
- 241000782597 Hypericum erectum Species 0.000 abstract 3
- 210000003813 thumb Anatomy 0.000 abstract 3
- 208000019255 Menstrual disease Diseases 0.000 abstract 1
- 241000209504 Poaceae Species 0.000 abstract 1
- 206010039897 Sedation Diseases 0.000 abstract 1
- 206010042674 Swelling Diseases 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000036280 sedation Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010015719 Exsanguination Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、抗潰瘍剤に関する。更
に詳しくは、植物からの抽出物を有効成分とする抗潰瘍
剤に関する。TECHNICAL FIELD The present invention relates to an antiulcer agent. More specifically, it relates to an anti-ulcer agent containing an extract from a plant as an active ingredient.
【0002】[0002]
【従来の技術】今日迄に抗潰瘍作用を示す数多くの化合
物が報告されているが、それらの多くは化学的手段によ
り合成されたものであり、それらの性質上連続的な服用
による様々な副作用を避け得ないのが現状である。BACKGROUND OF THE INVENTION To date, many compounds having antiulcer activity have been reported, but most of them have been synthesized by chemical means, and due to their nature, various side effects due to continuous administration are observed. The situation is unavoidable.
【0003】[0003]
【発明が解決しようとする課題】本発明の目的は、副作
用のない植物からの抽出物を有効成分とする抗潰瘍剤を
提供することにある。SUMMARY OF THE INVENTION It is an object of the present invention to provide an antiulcer agent containing an extract from a plant, which has no side effect, as an active ingredient.
【0004】[0004]
【課題を解決するための手段】かかる本発明の目的は、
オトギリソウの有機溶媒抽出物または有機溶媒水溶液抽
出物を有効成分として含有する抗潰瘍剤によって達成さ
れる。The object of the present invention is as follows.
This is achieved by an anti-ulcer drug containing an organic solvent extract or an organic solvent aqueous solution extract of Hypericum perforatum as an active ingredient.
【0005】オトギリソウは、北海道を除く日本各地に
分布する多年草であり、原野や山地の日当たりの良い場
所に自生しており、高さは約40cm程で、葉は対生し、8
〜9月頃枝先に鮮やかな黄色の花を付ける。ところで、
その全草は止血、はれものなどの外用に、また月経不
順、鎮痛などの煎服として用いられているが、それが抗
潰瘍作用を有することは全く知られていない。Hypericum perforatum, which is a perennial plant distributed in all parts of Japan except Hokkaido, grows naturally in sunny places in the wilderness and mountains, and has a height of about 40 cm.
Around September, bright yellow flowers are attached to the branches. by the way,
The whole plant is used externally for hemostasis, swelling, etc., and as a decoction for menstrual irregularities, analgesia, etc., but it is not known at all to have an anti-ulcer effect.
【0006】本発明においては、好ましくは夏から秋に
かけて採取されたオトギリソウの全草を乾燥後または未
乾燥のまま粉砕し、常温もしくは加熱下での有機溶媒抽
出物または有機溶媒水溶液抽出物が抗潰瘍剤の有効成分
として用いられる。有機溶媒としては、メタノール、エ
タノールなどのアルコール類が好んで用いられ、その水
溶液として用いられる場合には約10%以上、好ましくは
約50〜75%の濃度で用いられる。[0006] In the present invention, preferably, whole plants of Hypericum perforatum collected from summer to autumn are pulverized after drying or undried, and an organic solvent extract or an organic solvent aqueous solution extract at room temperature or under heating is used as an extract. Used as an active ingredient in ulcer drugs. As the organic solvent, alcohols such as methanol and ethanol are preferably used, and when used as an aqueous solution thereof, the concentration is about 10% or more, preferably about 50 to 75%.
【0007】抽出物は、こげ茶乃至茶色の粉末として得
られ、それの急性毒性試験をWister系雄性ラットを用い
て行ったところ、5000mg/kg(p.o.)の経口投与でも死亡
例はなく、毒性がきわめて低く、安全性の高いことが確
認された。The extract was obtained as a dark brown to brown powder, and its acute toxicity test was conducted using male Wistar rats. No oral death of 5000 mg / kg (po) was observed and no toxicity was observed. Was confirmed to be extremely low and safe.
【0008】これらの抽出物は、医薬または食品の形態
で提供することができる。医薬として用いる場合には、
散剤、顆粒、錠剤、糖衣錠、カプセル、液剤などの形で
提供され、また食品として用いられる場合には、ガム、
キャンディ、ゼリ−、錠菓、飲料などの形で提供され
る。[0008] These extracts can be provided in the form of medicine or food. When used as a medicine,
It is provided in the form of powder, granules, tablets, dragees, capsules, liquids, etc., and when used as food, gum,
It is provided in the form of candies, jellies, confectionery, beverages, and the like.
【0009】[0009]
【発明の効果】オトギリソウの有機溶媒抽出物または有
機溶媒水溶液抽出物は、抗潰瘍作用を示している。即
ち、急性胃炎モデルに対する予防効果が認められ、アス
ピリン胃粘膜病変、エタノール胃粘膜病変、特にエタノ
ール胃粘膜病変に対して顕著な効果がみられ、このこと
から防御因子増強作用を有していると考えられる。The organic solvent extract or organic solvent aqueous solution extract of Hypericum perforatum exhibits antiulcer action. That is, a preventive effect was observed against an acute gastritis model, and a remarkable effect was observed against aspirin gastric mucosal lesions, ethanol gastric mucosal lesions, and particularly ethanol gastric mucosal lesions, which suggests that it has a protective factor-enhancing effect. Conceivable.
【0010】[0010]
【実施例】次に、実施例について本発明を説明する。EXAMPLES The present invention will now be described with reference to examples.
【0011】実施例 乾燥したオトギリソウの全草を粉砕し、その100gずつを
それぞれ1Lの75%エタノール水溶液、50%エタノール水
溶液または25%エタノール水溶液中に加え、40℃で24時
間振とうを行った後、不溶物のロ別、減圧下での溶媒の
除去を行い、こげ茶乃至茶色の粉末としての抽出物I(1
5.7g)、抽出物II(19.6g)および抽出物III(19.8g)を得
た。EXAMPLE [0011] Dried whole plant of Hypericum perforatum was crushed, 100 g of each was added to 1 L of 75% ethanol aqueous solution, 50% ethanol aqueous solution or 25% ethanol aqueous solution, and shaken at 40 ° C for 24 hours. After that, the insoluble matter was separated by filtration, and the solvent was removed under reduced pressure, and the extract I (1
5.7 g), extract II (19.6 g) and extract III (19.8 g) were obtained.
【0012】これらの抽出物を、0.5%ナトリウムカルボ
キシメチルセルロース水溶液で2%または20%けん濁液に
調製し、ラット(6週令の雄性Crj:Wisterを購入後、1週
間検疫馴化したもの)にそれらを5ml/kg(2%けん濁液では
100mg/kgに、20%けん濁液では1000mg/kgにそれぞれ相当
する)の割合で、金属製胃ゾンデを用いて強制経口投与
し、潰瘍誘発剤投与の前処置を行った。なお、対照群に
は、0.5%ナトリウムカルボキシメチルセルロース水溶液
を同用量投与した。These extracts were prepared into 2% or 20% suspensions with 0.5% aqueous sodium carboxymethylcellulose solution, and then used in rats (6 weeks old male Crj: Wister purchased and quarantine-acclimated for 1 week). 5 ml / kg (2% suspension
The ulcer-inducing agent was pretreated by oral gavage at a ratio of 100 mg / kg and 1000 mg / kg for a 20% suspension). The control group was administered with 0.5% aqueous sodium carboxymethyl cellulose solution at the same dose.
【0013】アスピリン胃粘膜病変に対する作用:ラッ
トを24時間絶食、24時間絶水後、0.5%ナトリウムカルボ
キシメチルセルロース水溶液にけん濁させたアスピリン
125mg/kgを2時間おきに2回経口投与し、2回目の投与終
了3時間後に、ラットをエーテル麻酔下で放血致死さ
せ、胃を摘出して1%ホルマリン液中に簡易固定して、潰
瘍発生の有無を肉眼的に観察すると共に、病変の長さを
測定した。なお、被検物質は、1回目のアスピリン投与1
時間前に経口投与した。Aspirin Action on gastric mucosal lesions: Aspirin suspended in 0.5% sodium carboxymethylcellulose aqueous solution after fasting rats for 24 hours and water for 24 hours
Oral administration of 125 mg / kg twice every 2 hours, and 3 hours after the end of the second administration, the rats were killed by exsanguination under ether anesthesia, the stomach was excised, and simple fixation in 1% formalin solution was performed to ulcer. The presence or absence of the occurrence was visually observed and the length of the lesion was measured. The test substance was the first aspirin administration 1
Oral administration was performed before the time.
【0014】得られた結果は、次の表1に示される。こ
の結果から、抽出物IおよびIIの1000mg/kg前処置群に
おいて、対照群と比較して、かなりの抑制効果が認めら
れる。 (以下余白) 表1 被検物質 前処置液濃度(mg/kg) 潰瘍長さ(mm) 抑制率(%) 対照 52 抽出物I 1000 10 80.8 100 40 23.1 抽出物II 1000 25 51.9 100 48 7.7 抽出物III 1000 35 32.7 100 40 23.1The results obtained are shown in Table 1 below. From these results, a considerable inhibitory effect is observed in the 1000 mg / kg pretreatment group of Extracts I and II as compared with the control group. (Margins below) Table 1 Pretreatment liquid concentration of test substance (mg / kg) Ulcer length (mm) Suppression rate (%) Control 52 Extract I 1000 10 80.8 100 40 23.1 Extract II 1000 25 51.9 100 48 7.7 Extract Thing III 1000 35 32.7 100 40 23.1
【0015】エタノール胃粘膜病変に対する作用:ラッ
トを24時間絶食絶水後、無水エタノール1.0mlを経口投
与し、1時間後にエーテル麻酔下で放血致死させ、胃を
摘出して1%ホルマリン液中に簡易固定して、潰瘍発生の
有無を肉眼的に観察すると共に、病変の長さを測定し
た。なお、被検物質は、エタノール投与1時間前に経口
投与した。Effect on ethanol gastric mucosal lesion: After fasting and starvation of rats for 24 hours, 1.0 ml of absolute ethanol was orally administered, and 1 hour later, the animals were killed by exsanguination under ether anesthesia, and the stomach was excised and placed in 1% formalin solution. After simple fixation, the presence or absence of an ulcer was visually observed and the length of the lesion was measured. The test substance was orally administered 1 hour before the administration of ethanol.
【0016】得られた結果は、次の表2に示される。こ
の結果から、すべての抽出物の前処置群において、用量
依存的に抑制効果が認められる。 表2 被検物質 前処置液濃度(mg/kg) 潰瘍長さ(mm) 抑制率(%) 対照 135 抽出物I 1000 0 100 100 60 55.6 抽出物II 1000 5 96.3 100 85 37.0 抽出物III 1000 37 72.6 100 103 23.7The results obtained are shown in Table 2 below. From these results, a suppressive effect is observed in a dose-dependent manner in the pretreatment group of all extracts. Table 2 Pretreatment liquid concentration of test substance (mg / kg) Ulcer length (mm) Suppression rate (%) Control 135 Extract I 1000 0 100 100 60 55.6 Extract II 1000 5 96.3 100 85 37.0 Extract III 1000 37 72.6 100 103 23.7
Claims (1)
機溶媒水溶液抽出物を有効成分として含有してなる抗潰
瘍剤。1. An anti-ulcer agent comprising an organic solvent extract of Hypericum perforatum or an organic solvent aqueous solution extract as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4075927A JPH05238942A (en) | 1992-02-28 | 1992-02-28 | Antiulcerous agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4075927A JPH05238942A (en) | 1992-02-28 | 1992-02-28 | Antiulcerous agent |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH05238942A true JPH05238942A (en) | 1993-09-17 |
Family
ID=13590409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4075927A Pending JPH05238942A (en) | 1992-02-28 | 1992-02-28 | Antiulcerous agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH05238942A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4132025A1 (en) * | 1991-09-26 | 1993-04-01 | Hell Ag Linotype | LIGHT BEAM DEFLECTOR |
CN103720840A (en) * | 2013-12-27 | 2014-04-16 | 杨明英 | Traditional Chinese medicine composition for treating acute gastritis |
-
1992
- 1992-02-28 JP JP4075927A patent/JPH05238942A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4132025A1 (en) * | 1991-09-26 | 1993-04-01 | Hell Ag Linotype | LIGHT BEAM DEFLECTOR |
CN103720840A (en) * | 2013-12-27 | 2014-04-16 | 杨明英 | Traditional Chinese medicine composition for treating acute gastritis |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schmeda-Hirschmann et al. | Traditional medicine and gastroprotective crude drugs | |
Ilavarasan et al. | Anti-inflammatory and free radical scavenging activity of Ricinus communis root extract | |
KR100934955B1 (en) | Pharmaceutical compositions and methods of using the same | |
US5130133A (en) | Plant extracts as mucosal-protective agents | |
Chawla et al. | A review of chemistry and biological activities of the genus Aerva--a desert plant | |
Aher et al. | Therapeutic importance of fenugreek (Trigonella foenum-graecum L.): a review | |
US7025995B2 (en) | Antiulcer herbal composition(s) | |
KR102247702B1 (en) | Composition for preventing or treating gastritis or peptic ulcer | |
JP2002020302A (en) | Liver protecting agent having anti-oxidant action | |
KR101346066B1 (en) | Pharmaceutical composition containing Yellow-popular bark extract as active ingredient | |
JPH05238942A (en) | Antiulcerous agent | |
Arruda et al. | Gastroprotective effect of Serjania erecta Radlk (Sapindaceae): involvement of sensory neurons, endogenous nonprotein sulfhydryls, and nitric oxide | |
US20240115644A1 (en) | Composition for preventing, improving or treating gastritis or peptic ulcer comprising extract of cinnamomum cassia, fraction of said extract, isolate of said fraction or compounds isolated therefrom | |
WO2018172436A1 (en) | Formulations comprising active agents derived from the plant murraya koenigii | |
JP2004143126A (en) | Gastric mucosa-protecting agent | |
Ahmad et al. | Molecular docking and In vivo gastroprotective effect of Salvia fruticosa | |
WO2022003726A1 (en) | Antioxidant herbal composition in seamless capsules for cigarette filter application | |
Gupta et al. | Evaluation of protective effect of Butea monosperma (lam.) Taub in experimental hepatotoxicity in rats | |
US20080199543A1 (en) | Pharmaceutically Active Extracts of Vitex Leucoxylon, a Process of Extracting the Same and a Method of Treating Diabetes and Inflammatory Diseases Therewith | |
Patil et al. | Anti-inflammatory effect of Polyherbal Formulation | |
Tawfika et al. | A comparative study of antioxidant activities of ziziphus and colocynth from Saudi Arabia deserts and proposed pharmaceutical products | |
KR0163813B1 (en) | Extraction and Purification of Active Active Ingredients from Phosphorus and Herbal Composition Containing the Extracts | |
KR100832056B1 (en) | Sumac tea bag and method of making same | |
CN1935804A (en) | Medicine intermediate applepolyphenol extracting process | |
Nipun et al. | Antidiabetic, Analgesic, Antioxidant and Antimicrobial Potentials of Methanol Extracts of Fruits and Shoots of Brassica oleracea L. Var. Italic. |